The current average analyst rating on the shares is "hold" and the breakdown of recommendations is 6 "strong buy" or "buy", 6 "hold" and 2 "sell" or "strong sell"
The average consensus recommendation for the biotechnology & medical research peer group is "buy"
Wall Street's median 12-month price target for Rocket Pharmaceuticals, Inc. is $10.00, about 177% above its August 7 closing price of $3.61
Cash position and outlook
Company ended Q2 with $283.7 mln cash and expects its cash, cash equivalents and investments to fund operations into Q2 2028
Company expects to provide a regulatory update on the Danon disease program in H2 2026
Rocket anticipates commercial availability and patient onboarding for KRESLADI in Q4 2026
Quarterly results and profit driver
US biotech firm reported Q2 net income after KRESLADI approval and PRV sale
R&D and G&A expenses fell yr/yr due to lower headcount and commercial costs
The net income increase was helped by the $178 mln gain from the sale of a Priority Review Voucher after KRESLADI approval
RCKT•
